PATENT CLAIM ANALYSIS

Application Number: 16000678
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-06
Patent Classification: ["514", "275000"]

Abstract:
Disclosed herein is a method for modulating Program Death Receptor Ligand 1 (PDL1) in a cancer cell, comprising contacting the cell with a composition comprising a histone deacetylase (HDAC) inhibitor. Also disclosed is a method for treating a tumor in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising a histone deacetylase (HDAC) inhibitor and a composition comprising a therapeutically effective amount of a Program Death Receptor Ligand 1 (PDL1) inhibitor, a Programmed Death 1 receptor (PD1) inhibitor, or a combination thereof.

Claim (Index 1):
A method for modulating Program Death Receptor Ligand 1 (PDL1) in a cancer cell, comprising contacting the cell with a composition comprising a histone deacetylase (HDAC) inhibitor.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 94.0
- Lexical Diversity: 2.21277
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15120065', '15695435', '14907321', '15231187', '15120053']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.748971621161971
- 35 USC 102 Novelty (BERT): 0.5951540703843802
- Combined Prediction Score: 0.733589866084212
- Mean Citation Score: 395.918044
- Max Citation Score: 555.71234
- Similarity Product: 411.4296180225624

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test